Pasithea Therapeutics Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $14.9M
- Price
- $0.447
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.74%
- Volume
- 64.4K
About
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Quick stats
Shares outstanding33.4M
Computed float33.0M
Float / shares98.9%
Cash runway (months)25.9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001841330
Websitehttps://www.pasithea.com
AI Summary
AI-generated1/12
minorneutralclinical trial
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
Pasithea Therapeutics will present initial Part A clinical data from its ongoing Phase 1/1b trial of PAS-004 in adults with NF1 at the 2026 European Neurofibromatosis Conference, taking place November 12-14, 2026 in Vienna, Austria.
The data will be shown in two formats: an oral presentation on cutaneous neurofibromas by Rebecca Brown, MD of the University of Alabama at Birmingham (Nov 13, 08:00-09:30 CET), and a poster on plexiform neurofibromas presented by CEO Tiago Reis Marques (Nov 12).
This will be the company's first public disclosure of clinical data from Part A of the trial, and a follow-up press release with detailed results is planned at the time of presentation.
PAS-004, a next-generation macrocyclic oral MEK inhibitor, is also in a Phase 1 trial in advanced cancer patients, in addition to the Phase 1/1b NF1 study.
Red flags
- No clinical data, safety, or efficacy results disclosed in this release; actual results not available until the November 12-14, 2026 presentations